Drug Repositioning for Ovarian Cancer Treatment: An Update

Area of Science:

• Oncology
• Pharmacology
• Drug Discovery

Background:

• Ovarian cancer (OC) is a prevalent female reproductive malignancy with a poor 5-year survival rate below 45%.
• Current surgical and chemotherapeutic treatments for OC remain challenging.
• There is an urgent need for novel anticancer agents to improve patient outcomes.

Purpose of the Study:

• To review and update the status of promising drugs that can be repurposed for ovarian cancer treatment.
• To explore the potential of drug repositioning as a strategy for developing new OC therapies.
• To identify established drugs with known safety and pharmacokinetic profiles for potential OC application.

Main Methods:

• Literature review of existing studies on drug repositioning for ovarian cancer.
• Analysis of preclinical and clinical data for repurposed drug candidates.
• Evaluation of drug safety and pharmacokinetic profiles.

Main Results:

• Identification of several drug candidates with potential for ovarian cancer treatment and/or prevention.
• Demonstration of drug repositioning as a viable strategy to accelerate OC therapy development.
• Highlighting drugs with established human safety and pharmacokinetic data.

Conclusions:

• Drug repositioning presents a significant opportunity to discover new ovarian cancer therapies efficiently.
• Repurposed drugs can offer a faster and more cost-effective route to clinical application compared to de novo drug development.
• Further investigation into these promising agents could lead to improved treatments for ovarian cancer.